Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Measurable Residual Disease”

433 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 433 results

Testing effectiveness (Phase 2)Ended earlyNCT01088035
What this trial is testing

Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma

Who this might be right for
Ependymoma
Ann & Robert H Lurie Children's Hospital of Chicago 75
Testing effectiveness (Phase 2)Looking for participantsNCT05343013
What this trial is testing

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Who this might be right for
Colorectal Cancer
M.D. Anderson Cancer Center 25
Not applicableLooking for participantsNCT06744296
What this trial is testing

Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Massachusetts Eye and Ear Infirmary 75
Not applicableUnknownNCT02872662
What this trial is testing

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

Who this might be right for
MDSSCTMRD
Nordic MDS Group 200
Not applicableStudy completedNCT02716103
What this trial is testing

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

Who this might be right for
Amyloidosis
Boston Medical Center 45
Early research (Phase 1)Looking for participantsNCT06138587
What this trial is testing

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Myeloid LeukemiaLeukemiaLeukemia, Myeloid+3 more
Dana-Farber Cancer Institute 15
Not applicableActive Not RecruitingNCT02633111
What this trial is testing

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
B-cell Non-Hodgkin LymphomaAggressive
Memorial Sloan Kettering Cancer Center 501
Not applicableStudy completedNCT06000306
What this trial is testing

MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse

Who this might be right for
Measurable Residual Disease
Zhejiang University 192
Testing effectiveness (Phase 2)Study completedNCT02567253
What this trial is testing

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cancer
University Hospital, Ghent 56
Not applicableLooking for participantsNCT05959720
What this trial is testing

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Who this might be right for
Acute Lymphoid LeukemiaMinimal Residual DiseaseGene Abnormality+1 more
Instituto do Cancer do Estado de São Paulo 180
Testing effectiveness (Phase 2)Looking for participantsNCT05872724
What this trial is testing

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Who this might be right for
Cervical Cancer
Suzhou Municipal Hospital 32
Not applicableLooking for participantsNCT06198868
What this trial is testing

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT05289687
What this trial is testing

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Who this might be right for
T-cell Acute Lymphoblastic Leukemia
Eastern Cooperative Oncology Group 20
Large-scale testing (Phase 3)Study completedNCT00179829
What this trial is testing

WT1 for the Detection of Minimal Residual Disease

Who this might be right for
LeukemiaCancer
Ann & Robert H Lurie Children's Hospital of Chicago 50
Not applicableUnknownNCT03702088
What this trial is testing

Place of the Hevylite Test in the Evaluation of MRD in Myeloma

Who this might be right for
Myeloma
University Hospital, Montpellier 124
Not applicableLooking for participantsNCT05203003
What this trial is testing

Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

Who this might be right for
Multiple Myeloma
Assistance Publique - Hôpitaux de Paris 260
Testing effectiveness (Phase 2)UnknownNCT01894477
What this trial is testing

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia in RemissionChronic Myelomonocytic LeukemiaMinimal Residual Disease+3 more
Fred Hutchinson Cancer Center 102
Testing effectiveness (Phase 2)Temporarily pausedNCT05642195
What this trial is testing

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerNon-Small Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung+1 more
National Cancer Institute (NCI) 30
Early research (Phase 1)Study completedNCT02185781
What this trial is testing

Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Acute Lymphoblastic LeukemiaComplete Hematologic Remission (CHR)Persistent/Recurrent Minimal Residual Disease (MRD)
Gruppo Italiano Malattie EMatologiche dell'Adulto 6
Not applicableUnknownNCT05371873
What this trial is testing

Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer

Who this might be right for
Hepatocellular Carcinoma
First Affiliated Hospital of Zhejiang University 250
Load More Results